{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:14:36Z","timestamp":1780992876123,"version":"3.54.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,11,2]],"date-time":"2011-11-02T00:00:00Z","timestamp":1320192000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Imatinib mesylate has been the standard therapeutic treatment for chronic myeloid leukemia, advanced and metastatic gastrointestinal stromal tumor (GIST). It is well tolerated with mild adverse effects. Gynecomastia development during the course of treatment has been rarely reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Ninety-eight patients with advanced or recurrent GIST were treated with imatinib mesylate. Among the fifty-seven male patients six developed gynecomastia during the treatment. The lesions were confirmed by sonography. Sex hormone levels were determined in six patients with and without the presence of gynecomastia respectively. The patients with gynecomatia were treated with tamoxifene and the sex hormones were assayed before and after tamoxifene treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In patients with gynecomastia the lump underneath the bilateral nipples was 2.5 to 5 centimeters in diameter. Their serum free testosterone levels ranged between 356.61 and 574.60 ng\/dl with a mean \u00b1 SD of 408.64 \u00b1 82.06 ng\/dl (95% CI 343.03~474.25 ng\/dl), which is within the normal range. The level of serum estradiol was 42.89 \u00b1 16.54 pg\/ml (95% CI 29.66~56.12 pg\/ml). Three patients had higher levels (43.79~71.21 pg\/ml) and the others' were within normal range of 27.00~34.91 pg\/ml. Six patients without the development of gynecomastia had normal free testosterone. One patient died because of large tumor burden. The sex hormones had no significant changes before and after tamoxifene treatment.(<jats:italic>P<\/jats:italic> &gt; 0.05)<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Testosterone levels were not decreased in the six GIST patients with gynecomastia. Three patients had increased serum estradiol level which suggests that imbalance of sex hormones may be the cause of gynecomastia during treatment with imatinib mesylate.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-230x-11-116","type":"journal-article","created":{"date-parts":[[2011,11,17]],"date-time":"2011-11-17T14:09:32Z","timestamp":1321538972000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Gynecomastia during imatinib mesylate treatment for gastrointestinal stromal tumor: a rare adverse event"],"prefix":"10.1186","volume":"11","author":[{"given":"HeLi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GuoQing","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZhongShu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,11,2]]},"reference":[{"key":"649_CR1","first-page":"4771","volume":"26","author":"V Ferraresi","year":"2006","unstructured":"Ferraresi V, Catrical\u00e0 C, Ciccarese M, Ferrari A, Zeuli M, Cognetti F: Severe skin reaction in a patient with gastrointestinal stromal tumor treated with imatinib mesylate. Anticancer Res. 2006, 26: 4771-4774.","journal-title":"Anticancer Res"},{"key":"649_CR2","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1016\/S0140-6736(03)13554-4","volume":"361","author":"C Gambacorti-Passerini","year":"2003","unstructured":"Gambacorti-Passerini C, Tornaghi L, Cavagnini F, Rossi P, Pecori-Giraldi F, Mariani L, Cambiaghi N, Pogliani E, Corneo G, Gnessi L: Gynecomastia in men with myeloid leukemia after imatinib. Lancet. 2003, 361: 1951-1956.","journal-title":"Lancet"},{"key":"649_CR3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3346\/jkms.2005.20.3.512","volume":"20","author":"H Kim","year":"2005","unstructured":"Kim H, Chang HM, Ryu MH, Kim TW, Sohn HJ, Kim SE, Kang HJ, Park S, Lee JS, Kang YK: Concurrent male gynecomastia and testicular hydrocele after imatinib mesylate treatment of a gastrointestinal tumor. J Korean Med Sci. 2005, 20: 512-515. 10.3346\/jkms.2005.20.3.512.","journal-title":"J Korean Med Sci"},{"key":"649_CR4","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1038\/leu.2008.106","volume":"22","author":"G Caocci","year":"2008","unstructured":"Caocci G, Atzeni S, Orr\u00f9 N, Azzena L, Martorana L, Littera R, Ledda A, La Nasa G: Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia. Leukemia. 2008, 22: 2127-2128. 10.1038\/leu.2008.106.","journal-title":"Leukemia"},{"key":"649_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/MOP.0b013e328306a07c","volume":"20","author":"CA Nordt","year":"2008","unstructured":"Nordt CA, DiVasta AD: Gynecomastia in adolescents. Curr Opin Pediatr. 2008, 20: 375-382. 10.1097\/MOP.0b013e328306a07c.","journal-title":"Curr Opin Pediatr"},{"key":"649_CR6","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/ajcp\/57.4.431","volume":"57","author":"GA Bannayan","year":"1972","unstructured":"Bannayan GA, Haidu SI: Gynecomastia: clinicopathologic study of 351 cases. Am J Clin Pathol. 1972, 57: 431-437.","journal-title":"Am J Clin Pathol"},{"key":"649_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1677\/erc.0.0060315","volume":"6","author":"GD Braunnstein","year":"1999","unstructured":"Braunnstein GD: Aromatase and gynecomastia. Endocr Related Cancer. 1999, 6: 315-324. 10.1677\/erc.0.0060315.","journal-title":"Endocr Related Cancer"},{"key":"649_CR8","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1056\/NEJMcp070677","volume":"357","author":"GD Braunnstein","year":"2007","unstructured":"Braunnstein GD: Gynecomastia. New Engl J Med. 2007, 357: 1229-1237. 10.1056\/NEJMcp070677.","journal-title":"New Engl J Med"},{"key":"649_CR9","doi-asserted-by":"publisher","first-page":"672","DOI":"10.4065\/84.8.672","volume":"84","author":"BA Haynes","year":"2009","unstructured":"Haynes BA, Mookadam F: Male gynecomastia. Mayo Clin Proc. 2009, 84: 672-10.4065\/84.8.672.","journal-title":"Mayo Clin Proc"},{"key":"649_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.critrevonc.2005.06.007","volume":"57","author":"C Walz","year":"2006","unstructured":"Walz C, Sattler M: Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Critic Rew Oncol Hematol. 2006, 57: 145-164. 10.1016\/j.critrevonc.2005.06.007.","journal-title":"Critic Rew Oncol Hematol"},{"key":"649_CR11","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1210\/jc.87.5.2310","volume":"87","author":"S Basciani","year":"2002","unstructured":"Basciani S, Mariani S, Arizzi M, Ulisse S, Rucci N, Jannini EA, Della Rocca C, Manicone A, Carani C, Spera G, Gnessi L: Expression of platelet-derived growth factor-A(PDGFR-A) and PDGFR receptor-alpha and beta during human testicular development and disease. J Clin Endocrinol Metab. 2002, 87: 2310-2319. 10.1210\/jc.87.5.2310.","journal-title":"J Clin Endocrinol Metab"},{"key":"649_CR12","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1101\/gad.1723908","volume":"22","author":"J Schmahl","year":"2008","unstructured":"Schmahl J, Rizzolo K, Soriano P: The PDGF signaling pathway controls multiple steroid-producing lineages. Genes Dev. 2008, 22: 3255-3267. 10.1101\/gad.1723908.","journal-title":"Genes Dev"},{"key":"649_CR13","first-page":"599","volume":"44","author":"C Sette","year":"2000","unstructured":"Sette C, Dolci S, Geremia R, Rossi P: The role of stem cell factor and of alternative c-Kit gene products in the establishment, maintenance and function of germ cells. Int J Dev Biol. 2000, 44: 599-608.","journal-title":"Int J Dev Biol"},{"key":"649_CR14","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S0090-4295(00)00823-2","volume":"56","author":"DG McLeod","year":"2000","unstructured":"McLeod DG, Iversen P: Gynecomastia in patients with prostate cancer: a review of treatment options. Urology. 2000, 56: 713-720. 10.1016\/S0090-4295(00)00823-2.","journal-title":"Urology"},{"key":"649_CR15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2165\/00003088-200544040-00002","volume":"44","author":"B Rochat","year":"2005","unstructured":"Rochat B: Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clin Pharmacokinet. 2005, 44: 349-366. 10.2165\/00003088-200544040-00002.","journal-title":"Clin Pharmacokinet"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-230X-11-116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-230X-11-116\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-230X-11-116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-230X-11-116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T17:11:03Z","timestamp":1630516263000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/1471-230X-11-116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,2]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["649"],"URL":"https:\/\/doi.org\/10.1186\/1471-230x-11-116","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,2]]},"assertion":[{"value":"22 May 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"116"}}